GLP-1 receptor agonists achieve substantial weight loss but cause frequent gastrointestinal side effects and weight regain upon discontinuation, while dietary fibers naturally stimulate endogenous GLP-1 through microbial fermentation with more modest but sustainable effects. Both pathways converge on the same gut-brain appetite control mechanisms, suggesting strategic combination therapy could amplify benefits while minimizing drawbacks. This mechanistic overlap presents a compelling opportunity to revolutionize obesity treatment by using fiber as both a therapeutic enhancer and safety buffer. The proposed framework positions fiber as foundational care that could reduce dependence on expensive GLP-1 drugs, potentially addressing the healthcare cost crisis in obesity management. However, the interaction dynamics remain largely theoretical—fiber's impact on drug absorption during slowed gastric emptying, potential GLP-1 receptor desensitization, and optimal timing protocols are uncharted territory. The approach could transform obesity care from episodic pharmaceutical intervention to sustained lifestyle-integrated management, but rigorous clinical trials measuring microbiome endpoints and long-term outcomes are essential before clinical implementation.